Immunomodulatory Agent
BLd Combination Therapy for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
CAR T-cell Therapy
TAA-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Recruiting1 awardPhase 1
Houston, Texas
This trial is for patients with Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS), or smoldering myeloma (SM). The goal is to find the largest safe dose of TAA-specific CTLs (a new experimental therapy), and to see whether it might help patients by targeting proteins that are expressed by cancer cells.
Corticosteroid
Pomalidomide + Dexamethasone +/- Daratumumab for Multiple Myeloma
Recruiting1 awardPhase 2
Tucson, Arizona
This trial will evaluate the efficacy of pomalidomide and low-dose dexamethasone or the combination of pomalidomide, daratumumab, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma.
Popular Filters
Trials for MM (Multiple Myeloma) Patients
Immunomodulatory Agent
Triple Drug Therapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat cancer. The drugs are lenalidomide, bortezomib, and dexamethasone. They are testing it in patients with multiple myeloma who have not been treated before.
Monoclonal Antibodies
PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing the safety of CT-011 and the combination of the Dendritic cell fusion vaccine and CT-011 after ASCT in patients with multiple myeloma. They are also testing to see if the combination is more successful in preventing or delaying the disease from coming back, compared to treatment with ASCT alone.
Trials for Burkitt Lymphoma Patients
Anti-metabolites
Cord Blood Transplant for Leukemia
Recruiting3 awards4 criteria
Minneapolis, Minnesota
This trial is testing a new way to treat leukemia with an unrelated umbilical cord blood transplant. The transplant will use a myeloablative preparative regimen, which will include the drugs cyclophosphamide, fludarabine, and fractionated total body irradiation.
Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
Recruiting1 award11 criteria
Boston, Massachusetts
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
Antimetabolites
UCB Transplant After Non-Myeloablative Prep for Blood Cancers
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new cancer treatment that uses a less intense form of chemotherapy followed by a bone marrow transplant. The new treatment is based on the patient's diagnosis, disease status, and prior treatment.
Checkpoint Inhibitor
Targeted Therapy for Advanced Stage Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying how well different targeted drugs work in treating patients with cancer that has progressed after other treatments and has a genomic variant that makes the tumor respond to the drug.
Trials for Metastatic Patients
Antimetabolites
UCB Transplant After Non-Myeloablative Prep for Blood Cancers
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new cancer treatment that uses a less intense form of chemotherapy followed by a bone marrow transplant. The new treatment is based on the patient's diagnosis, disease status, and prior treatment.
Checkpoint Inhibitor
Targeted Therapy for Advanced Stage Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying how well different targeted drugs work in treating patients with cancer that has progressed after other treatments and has a genomic variant that makes the tumor respond to the drug.
Immunomodulatory Agent
Ruxolitinib + Steroids + Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 1
Alhambra, California
This trial tests a combination of ruxolitinib, steroids, and lenalidomide in multiple myeloma patients who are not responding to current treatments. The drugs work together to block cancer growth signals, reduce inflammation, and enhance the immune response. Lenalidomide is an immunomodulatory drug developed from thalidomide, effective in multiple myeloma and approved by the FDA.
Hematopoietic Stem Cell Transplantation
HSCT for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new way to give an allogeneic HCT, which is a transplant of blood-forming cells from a donor. This new method uses a myeloablative preparative regimen, which is a way to kill cancer cells, followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen.
Phase 3 Trials
Immunomodulatory Agent
Triple Drug Therapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat cancer. The drugs are lenalidomide, bortezomib, and dexamethasone. They are testing it in patients with multiple myeloma who have not been treated before.
Chemotherapy
TT3-LITE Regimen for Multiple Myeloma
Recruiting4 awardsPhase 3
Little Rock, Arkansas
This trial is testing a cancer treatment called S-TT3, which uses high-dose chemotherapy to kill cancer cells. It targets patients needing strong chemotherapy and transplants. The goal is to reduce severe side effects while maintaining treatment effectiveness.
Topoisomerase II Inhibitor
Combination Chemotherapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Little Rock, Arkansas
This trial is continuing the research from Total Therapy I and II to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease.
Bcl-2 Inhibitor
Venetoclax + Dexamethasone vs Pomalidomide + Dexamethasone for Multiple Myeloma
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is studying whether a combination of venetoclax and dexamethasone is better than pomalidomide and dexamethasone at treating patients with relapsed or refractory multiple myeloma.
Trials With No Placebo
Immunomodulatory Agent
Triple Drug Therapy for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat cancer. The drugs are lenalidomide, bortezomib, and dexamethasone. They are testing it in patients with multiple myeloma who have not been treated before.
Monoclonal Antibodies
PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing the safety of CT-011 and the combination of the Dendritic cell fusion vaccine and CT-011 after ASCT in patients with multiple myeloma. They are also testing to see if the combination is more successful in preventing or delaying the disease from coming back, compared to treatment with ASCT alone.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.